Contract research organization Genewiz has partnered with biotechnology company BeiGene to accelerate cancer biomarker discovery to support drug target identification
Under the deal, BeiGene will leverage OncoGxOne discovery cancer panels to identify and understand genetic variations in prevalent cancers all through China and the Asia-Pacific region.
BeiGene discovery biomarkers head Dr Lai Wang said, "Our collaboration with GENEWIZ and application of the OncoGxOne cancer panels will enable characterization of primary tumor models at the genetic level, with a focus on aberrations in cancer related genes."
As part of the portfolio of oncology target therapies in early stage development, Beijing-based BeiGene established several patient-derived primary tumor models in-house.
Translational Genomics vice president Dr Guanghui Hu said, "Due to the unique ability to detect aberrations including gene fusions and copy number variance (CNV), using OncoGxOne Discovery cancer panels we have capabilities to identify novel mutations present in BeiGene's primary cancer tumor models."